Now if we just had a strategy to identify candidate drugs for this. Ask your neurologist whom the hell needs to be contacted to identify drugs for this purpose. If your neurologist doesn't know that call the hospital president and have that person relieved of duty for not knowing how to practice medicine. If WE don't start taking a hard line with our stroke medical staff they will never fix any of the problems in stroke. Heads need to start rolling. Ranting in full force today, the president of the WSO really needs to justify the incompetency of that organization.
http://news.illinois.edu/news/14/1223gelatin_hyungsoochoi_kyekyoonkim.html
Stroke victims could have more time to seek treatment that could
reduce harmful effects on the brain, thanks to tiny blobs of gelatin
that could deliver the medication to the brain noninvasively.
University of Illinois researchers and colleagues in South Korea, led by U. of I. electrical and computer engineering senior research scientist Hyungsoo Choi and professor Kyekyoon “Kevin” Kim, published details about the gelatin nanoparticles in the journal Drug Delivery and Translational Research.
The researchers found that gelatin nanoparticles could be laced with
medications for delivery to the brain, and that they could extend the
treatment window for when a drug could be effective. Gelatin is
biocompatible, biodegradable, and classified as “Generally Recognized as
Safe” by the Food and Drug Administration. Once administered, the
gelatin nanoparticles target damaged brain tissue thanks to an
abundance of gelatin-munching enzymes produced in injured regions.
The tiny gelatin particles have a huge benefit: They can be
administered nasally, a noninvasive and direct route to the brain. This
allows the drug to bypass the blood-brain barrier, a biological fence
that prevents the vast majority of drugs from entering the brain
through the bloodstream.
“Overcoming the difficulty of delivering therapeutic agents
to specific regions of the brain presents a major challenge to treatment
of most neurological disorders,” said Choi. “However, if drug
substances can be transferred along the olfactory nerve cells, they can
bypass the blood-brain barrier and enter the brain directly.”
To test gelatin nanoparticles as a drug-delivery system, the
researchers used the drug osteopontin (OPN), which in rats can help to
reduce inflammation and prevent brain cell death if administered
immediately after a stroke.
“It is crucial to treat ischemic strokes within three hours to
improve the chances of recovery. However, a significant number of
stroke victims don’t get to the hospital in time for the treatment,” Kim
said.
By lacing gelatin nanoparticles with OPN, the researchers
found that they could extend the treatment window in rats, so much so
that treating a rat with nanoparticles six hours after a stroke showed
the same efficacy rate as giving them OPN alone after one hour – 70
percent recovery of dead volume in the brain.
The researchers hope the gelatin nanoparticles, administered
through the nasal cavity, can help deliver other drugs to more
effectively treat a variety of brain injuries and neurological diseases.
“Gelatin nanoparticles are a delivery vehicle that could be used to
deliver many therapeutics to the brain,” Choi said. “They will be most
effective in delivering drugs that cannot cross the blood-brain barrier.
In addition, they can be used for drugs of high toxicity or a short
half-life.“
Both Choi and Kim are members of the Micro and Nano Technology Laboratory at the U. of I. Kim is also affiliated with the Neuroscience Program, the Institute for Genomic Biology, the Beckman Institute and the departments of bioengineering, of materials science and engineering, and of nuclear, plasma and radiological engineering at the U. of I.
No comments:
Post a Comment